MLV & Co

In a report published Thursday, MLV & Co. analyst Richard Eckert upgraded the rating on Resource Capital Corp. (NYSE: RSO) from Hold to Buy, and reiterated a $6.00 price target. In the report, MLV & Co noted, “Notwithstanding small cuts to our estimates of 2014 and 2015 AFFO/Share, we are...

In a report published Tuesday, MLV & Co analyst Paul Morgan reiterated a Buy rating and $31.00 price target on Sabra Health Care REIT (NASDAQ: SBRA). In the report, MLV & Co noted, “Sabra's $550M portfolio acquisition of 21 private-pay, Holiday Retirement communities weighed on SBRA shares...

In a report published Monday, MLV & Co analyst Chad Mabry reiterated a Buy rating on Gastar Exploration (NYSE: GST), but lowered the price target from $11.00 to $9.00. In the report, MLV & Co noted, “GST recently closed a common stock offering of 17.0 million shares (19.55 including the...

In a report published Thursday, MLV & Co analyst Chad Mabry reiterated a Buy rating and $11.00 price target on Magnum Hunter Resources Corp. (NYSE: MHR). In the report, MLV & Co noted, “MHR's Stewart Winland 1300U (100% w.i.) tested at a peak rate of 46.5 MMcf/d on an adjustable rate choke...

In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galmed Pharmaceuticals Ltd (NASDAQ: GLMD), and raised the price target from $19.00 to $24.00. In the report, MLV & Co noted, “Galmed Pharmaceuticals (GLMD) yesterday announced FDA approval for...

In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $16.00 price target on Galectin Therapeutics Inc (NASDAQ: GALT). In the report, MLV & Co noted, “Galectin Therapeutics (GALT) earlier today announced issuance of a US patent for composition and...

In a report published Friday, MLV & Co analyst Paul Morgan reiterated a Buy rating and $20.00 price target on DDR Corp (NYSE: DDR). In the report, MLV & Co noted, “After the close, DDR announced that CEO Dan Hurwitz will be leaving the firm, as the Board and Mr. Hurwitz ‘have agreed not to...

In a report published Wednesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating on Galena Biopharma (NASDAQ: GALE), but lowered the price target from $5.00 to $3.00. In the report, MLV & Co noted, “We believe the negative reaction to Galena Biopharma's (GALE) disclosure of...

In a report published Thursday, MLV & Co analyst Richard Eckert reiterated a Hold rating and $6.00 price target on Resource Capital (NYSE: RSO). In the report, MLV & Co noted, “Last Tuesday, after the market close, RSO reported another muddy quarter. 2Q14 AFFO/Share of 19¢ was just a penny...

In a report published Tuesday, MLV & Co analyst Chad Mabry reiterated a Hold rating on FX Energy (NASDAQ: FXEN). In the report, MLV & Co noted, “FXEN reported adj. Q2'14 EPS of $0.05, beating our breakeven estimate and the ($0.03) consensus. Adj. EPS excludes $3.7 million of impairments and...

In a report published Monday, MLV & Co analyst Chad Mabry reiterated a Buy rating and $11.00 price target on Gastar Exploration (NYSE: GST). In the report, MLV & Co noted, “GST reported Q2'14 adj. EPS of $0.12, beating both the $0.02 consensus and our $0.01 estimate. CFPS of $0.30 also...

In a report published Monday, MLV & Co analyst Chad Mabry reiterated a Buy rating and $11.00 price target on Magnum Hunter Resources (NYSE: MHR). In the report, MVL & Co noted, “MHR reported Q2'14 adj. EPS of ($0.09), beating our estimate of ($0.12) and the consensus of ($0.17). The driver...

In a report published Monday, MLV & Co analyst Chad Mabry reiterated a Hold rating on Bonanza Creek Energy (NYSE: BCEI). In the report, MLV & Co noted, “BCEI reported Q2'14 adj. EPS of $0.52, missing the $0.68 Street consensus and our $0.73 estimate. Adjusted EPS excludes $21 million of...

In a report published Monday, MLV & Co analyst Chad Mabry reiterated a Buy rating and $87.00 price target on PDC Energy (NASDAQ: PDCE). In the report, MLV & Co noted, “PDCE reported Q2'14 adj. EPS of $0.23, missing our $0.38 estimate and the $0.34 Street consensus. CFPS of $1.95 was just...

In a report published Monday, MLV & Co analyst Richard Eckert reiterated a Hold rating on New York Mortgage Trust (NASDAQ: NYMT), and raised the price target from $7.45 to $7.50. In the report, MLV & Co noted, “NYMT reported a record quarterly net income of $30.3mm, $0.34/share, largely as...